IMUN Immune Therapeutics Inc (PK)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2024

 

OR

 

☐ TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934

 

From the transition period from ___________ to ____________

 

Commission File Number 000-54933

 

BIOSTAX CORP

(Exact name of small business issuer as specified in its charter)

 

Florida		59-3226705
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

2431 Aloma Ave., Suite 124, Winter Park, FL		32792
(Address of principal executive offices)		(Zip Code)

 

888-613-8802

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by a check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

	Large Accelerated Filer ☐	Accelerated Filer ☐
	Non-Accelerated Filer ☐	Smaller Reporting Company ☒
		Emerging growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by a check mark whether the company is a shell company (as defined by Rule 12b-2 of the Exchange Act: Yes ☐ No ☒

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

As of May 20, 2024, there were 83,711,316 shares of common stock, $0.0001 par value per share, outstanding.

 

 

 

TABLE OF CONTENTS

 

	PART I – FINANCIAL STATEMENTS
Item 1.	Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Conditions and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21
Item 4.	Controls and Procedures	21
	PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	22
Item 1A.	Risk Factors	22
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	22
Item 3.	Default upon Senior Securities	22
Item 4.	Mine Safety Disclosure	22
Item 5.	Other Information	22
Item 6.	Exhibits	23

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Certain statements contained or incorporated by reference in this Quarterly Report on Form 10-Q are considered forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995) concerning our business, results of operations, economic performance and/or financial condition, based on management’s current expectations, plans, estimates, assumptions, and projections. Forward-looking statements are included, for example, in the discussions about:

 

	●	strategy;
	●	new product discovery and development;
	●	current or pending clinical trials;
	●	our products’ ability to demonstrate efficacy or an acceptable safety profile;
	●	actions by the U.S. Food and Drug Administration and other regulatory authorities;
	●	product manufacturing, including our arrangements with third-party suppliers;
	●	product introduction and sales;
	●	royalties and contract revenues;
	●	expenses and net income;
	●	credit and foreign exchange risk management;
	●	liquidity;
	●	asset and liability risk management;
	●	the outcome of litigation and other proceedings;
	●	intellectual property rights and protections;
	●	economic factors;
	●	competition; and
	●	legal risks.

 

Any statements contained in this report that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “plans,” “may,” “could,” “will,” “will continue,” “seeks,” “should,” “predict,” “potential,” “outlook,” “guidance,” “target,” “forecast,” “probable,” “possible” or the negative of such terms and similar expressions. Forward-looking statements are subject to change and may be affected by risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement in light of new information or future events, except as required by law, although we intend to continue to meet our ongoing disclosure obligations under the U.S. securities laws and other applicable laws.

 

 

We caution you that a number of important factors could cause actual results or outcomes to differ materially from those expressed in, or implied by, the forward-looking statements, and therefore you should not place too much reliance on them. These factors include, among others, those described herein, and elsewhere in this Quarterly Report and in our other public reports filed with the Securities and Exchange Commission. It is not possible to predict or identify all such factors, and therefore the factors that are noted are not intended to be a complete discussion of all potential risks or uncertainties that may affect forward-looking statements. If these or other risks and uncertainties materialize, or if the assumptions underlying any of the forward-looking statements prove incorrect, our actual performance and future actions may be materially different from those expressed in, or implied by, such forward-looking statements. We can offer no assurance that our estimates or expectations will prove accurate or that we will be able to achieve our strategic and operational goals.

 

Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

 

Important factors that could cause such differences include, but are not limited to:

 

	●	our lack of operating history;
	●	our current and future capital requirements and our ability to satisfy our capital needs;
	●	our inability to keep up with industry competition;
	●	interpretations of current laws and the passages of future laws;
	●	acceptance of our business model by investors and our ability to raise capital;
	●	our drug discovery and development activities may not result in products that are approved by the applicable regulatory authorities and even if our drug candidates do obtain regulatory approval, they may never achieve market acceptance or commercial success;
	●	our reliance on key personnel and collaborative partners, including our ability to attract and retain scientists;
	●	our reliance on third-party manufacturing to supply drugs for clinical trials and sales;
	●	our limited distribution organization with no sales and marketing staff;
	●	our being subject to product liability claims;
	●	legislation or regulation that may increase the cost of our business or limit our service and product offerings;
	●	risks related to our intellectual property, including our ability to adequately protect intellectual property rights;
	●	risks related to government regulation, including our ability to obtain approvals for the commercialization of some or all of our drug candidates, and ongoing regulatory obligations and continued regulatory review which may result in significant additional expense and subject us to penalties if we fail to comply with applicable regulatory requirements; and
	●	our ability to obtain regulatory approvals to allow us to market our products internationally.

 

Moreover, new risks regularly emerge, and it is not possible for our management to predict or articulate all risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included in this Quarterly Report are based on information available to us on the date of this Quarterly Report. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether because of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this Quarterly Report.

 

 

PART 1 – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

	Page
Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023	6
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2024 and 2023 (unaudited)	7
Condensed Consolidated Statement of Stockholders’ Equity/(Deficit) for Three Months Ended March 31, 2024 and 2023 (unaudited)	8
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023 (unaudited)	9
Notes to Condensed Consolidated Financial Statements (unaudited)	10

 

 

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

		March 31, 2024				December 31, 2023
			(Unaudited)
ASSETS
Current Assets:
Cash		$	2,098			$	29,785
Total current assets			2,098				29,785
Deposits			5,500				5,500
Total Assets		$	7,598			$	35,285
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Accounts payable		$	1,352,465			$	1,350,984
Accrued payroll			336,002				336,002
Notes payable, net of debt discount			1,243,402				1,222,876
Due to related parties			1,310,147				1,069,594
Accrued interest			182,440				152,315
Accrued liabilities			136,057				136,057
License fees payable			306,307				295,230
Total current liabilities			4,866,820				4,563,057
Total Liabilities			4,866,820				4,563,057
Stockholders’ Deficit:
Common stock – par value $0.0001; 750,000,000 and 750,000,000 shares authorized, respectively; 83,711,316 and 83,243,079 shares issued and outstanding respectively			8,374				8,366
Additional paid in capital			380,800,619				380,795,003
Accumulated deficit			(385,668,216	)			(385,331,140	)
Total stockholders’ deficit			(4,859,222	)			(4,527,772	)
Total Liabilities and Stockholders’ Deficit		$	7,598			$	35,285

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(Unaudited)

 

		March 31, 2024				March 31, 2022
		Three Months Ended
		March 31, 2024				March 31, 2023
Operating expenses:
Selling, general and administrative		$	254,250			$	207,517
Research and development expense			11,077				180,924
Depreciation and amortization expense			-				13,377
Total operating expenses			265,327				401,818
Loss from operations			(265,327	)			(401,818	)
Other (expense) income:
Interest expense			(71,749	)			(14,299	)
Total other (expense) income			(71,749	)			(14,299	)
Net loss		$	(337,076	)		$	(416,117	)
Basic (loss) income per share attributable to common shareholders		$	(0.00	)		$	(0.00	)
Diluted (loss) income per share to common shareholders		$	(0.00	)		$	(0.00	)
Basic weighted average number of shares outstanding			83,711,316				83,243,079
Diluted weighted average number of shares outstanding			85,782,403				83,243,079

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY/(DEFICIT)

FOR THE PERIODS ENDED MARCH 31, 2024 AND 2023

(Unaudited)

 

		Shares				Amount				Capital				Issued				Deficit				Total
		Common Stock								Additional Paid-in				Stock To Be				Accumulated
		Shares				Amount				Capital				Issued				Deficit				Total
Balance December 31, 2022			83,045,857			$	8,305			$	380,436,432			$	10,303			$	(382,968,494	)		$	(2,513,454	)
Issuance of common stock for extension of patent and license agreement			250,000				25				149,975				-				-				150,000
Net loss			-				-				-				-				(416,117	)			(416,117	)
Balance March 31, 2023			83,295,857			$	8,330			$	380,586,407			$	10,303			$	(383,384,611	)		$	(2,779,571	)
Balance December 31, 2023			83,657,853			$	8,366			$	380,795,002			$	-			$	(385,331,141	)		$	(4,527,772	)
Balance			83,657,853			$	8,366			$	380,795,002			$	-			$	(385,331,141	)		$	(4,527,772	)
Issuance of common stock upon conversion of notes and obligations			81,086				8				5,617				-				-				5,626
Net loss			-				-				-				-				(337,076	)			(337,076	)
Balance March 31, 2024			83,738,939			$	8,374			$	380,800,619			$	-			$	(385,668,217	)		$	(4,859,222	)
Balance			83,738,939			$	8,374			$	380,800,619			$	-			$	(385,668,217	)		$	(4,859,222	)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

IMMUNE THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(Unaudited)

 

		March 31, 2024				March 31, 2023
		Three Months Ended
		March 31, 2024				March 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		$	(337,076	)		$	(416,117	)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Loss on impairment on investment in common stock			-				-
Amortization of intangibles			-				13,377
Common stock issued for the extension of patent and license agreement			-				150,000
Changes in operating assets and liabilities:
Deposits			-				38,116
Accounts payable			1,482				-
License fees payable			11,077				(127,305	)
Accrued payroll			-				-
Accrued interest			30,125				14,299
Accrued liabilities			-				15,000
Due to related parties			240,553				47,132
Net cash used in operating activities			(53,839	)			(265,498	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of notes payable			26,151				150,000
Net cash provided by financing activities			26,151				150,000
Decrease in cash			(27,688	)			(115,498	)
Cash and cash equivalents, beginning of year			29,785				150,491
Cash and cash equivalents, end of year		$	2,098			$	34,993

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

 

Immune Therapeutics, Inc.

Notes to the Condensed Consolidated Financial Statements

March 31, 2024

(Unaudited)

 

1. Company Overview

 

Biostax Corp. (the “Company” or “BTAX”) is a Florida corporation trading on the OTC-Pink. The Company is a drug development and commercialization company. We identify, evaluate, and seek to acquire technologies in the medical device and drug development sectors with the intent to further develop them and move them to commercialization. On February 28, 2023, we received a written consent from a majority of our outstanding shareholders to change the name of our Company to “Biostax Corp.” On March 27, 2023, we filed a definitive information statement on Schedule 14C and mailed the information statement to shareholders on record as of the date of the filing. We filed our name change amendment with the Secretary of State of Florida on October 5, 2023 and our new Company name and trading symbol (BTAX) became effective on October 20, 2023.

 

Going Concern

 

As of March 31, 2024, the Company had $2,098 in cash on hand, negative working capital of $4,864,722 and accumulated stockholders’ deficit of $385,668,216. For the three months ended March 31, 2024, the Company reported a net loss attributable to common shareholders of $337,076. For the three months ended March 31, 2023, the Company reported a net loss attributable to common shareholders of $416,117.

 

Historically the Company has relied on the funding of operations through private equity financing and management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its current or future product candidates as they become available and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources.

 

Working capital at March 31, 2024 is not sufficient to meet the cash requirements to fund planned operations through the next twelve months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

 

Management is continuing to develop strategies to re-capitalize the Company and position it for future growth. Key steps to this process include:

 

	●	Improve the condition of the balance sheet via license arrangements and capital infusions.
	●	Identify and acquire late-stage assets for commercialization.
	●	Build out operational infrastructure to generate revenue opportunities to grow shareholder value.

 

There can be no guaranties that the Company will be successful in securing adequate capital to continue operations and in identifying and acquiring assets for future development.

 

10

 

If the Company is unable to secure new working capital, other alternatives strategies will be required.

 

Historically, the Company’s strategy has been to acquire and develop assets; potentially spin them out and retain both an equity stake and royalties and milestone payments. In so doing, the Company would act as an incubator for late-stage drug development. Management believes that this strategy can be successful. At this time, the Company is reviewing several opportunities which it may pursue as soon as funding is available. At present, no definitive action has been taken.

 

There can be no guarantees that the Company will be successful in:

 

	●	Executing its restructuring plan;
	●	Securing adequate capital to continue operations; or
	●	Identifying and acquiring assets for future development.

 

Company History

 

The Company was initially incorporated in Florida on December 2, 1993, as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. On February 28, 2023, we received a written consent from a majority of our outstanding shareholders to change the name of our Company to “Biostax Corp.” On March 27, 2023, we filed a definitive information statement on Schedule 14C and mailed the information statement to shareholders on record as of the date of the filing. We filed our name change amendment with the Secretary of State of Florida on October 5, 2023 and our new Company name and trading symbol (BTAX) became effective on October 20, 2023

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the consolidated financial position and consolidated results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These condensed, consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2023 (including the notes thereto) set forth in the Company’s Annual Report on Form 10- K/A for that period.

 

Use of Estimates

 

The preparation of the Company’s condensed, consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed, consolidated financial statements and accompanying notes. Actual results could differ from such estimates.

 

11

 

Cash, Cash Equivalents, and Short-Term Investments

 

The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value. At March 31, 2024 and December 31, 2023, the Company had cash and cash equivalents of $2,098 and $29,785, respectively.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000.

 

Segment and Geographic Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.

 

Fair Value of Financial Instruments

 

In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments.

 

Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.

 

Research and Development Costs

 

Research and development costs are charged to expense as incurred and are typically comprised of expenses associated with advancing the commercialization of our technologies. The Company incurred $11,077 of research and development costs during the three months ended March 31, 2024, which solely represents interest and late fees related to the Company’s license agreement with TaiwanJ Pharmaceuticals. The Company inclurred $180,924 of research and development costs during the three months ended March 31, 2023 which includes legal fees related to the maintenance and prosecution of licensed and owned intellectual property as well as the fair value of common stock issued to extend the payment terms of the Company’s license agreement with TaiwanJ Pharmaceuticals.

 

Income Taxes

 

The Company follows ASC Topic 740, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

 

12

 

The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.

 

At the date of adoption, and as of March 31, 2024 and 2023, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of March 31, 2024, and 2023, the Company does not have any interest or penalties related to uncertain tax positions.

 

Stock-Based Compensation and Issuance of Common Stock for Non-Cash Consideration

 

The Company measures and recognizes compensation expense for share-based awards based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement.

 

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “Compensation-Stock Compensation.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.

 

The Company did not issue any stock-based compensation awards during the three months ended March 31, 2024 and 2023.

 

Net Income (Loss) per Share

 

For the three months ended March 31, 2024, basic and diluted net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents.

 

13

 

For the three months ended March 31, 2024, diluted income per share was calculated by dividing the net income by the weighted-average number of common shares outstanding for the period determined using the treasury-stock method. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share for the periods ended March 31, 2024 and 2023 are as follows:

 

Schedule of Basic and Diluted Earnings per Share

		March 31, 2024				March 31, 2023
		Three Months ended
		March 31, 2024				March 31, 2023
Basic EPS
Income (loss) available to common shareholders (Numerator)		$	(337,076	)		$	(416,117	)
Weighted average common shares (Denominator)			83,711,316				83,243,079
Basic EPS		$	(0.00	)		$	(0.00	)
Diluted EPS
Income (loss) available to common shareholders (Numerator)		$	(337,076	)		$	(416,117	)
Weighted average common shares (Denominator)			85,782,403				83,243,079
Diluted EPS		$	(0.00	)		$	(0.00	)

 

Recent Accounting Standards

 

The Company has reviewed the accounting pronouncements issued by the FASB during the first quarter of 2024. Applicable pronouncements will be adopted by the Company in accordance with the accounting guidance and definition. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

 

Management does not believe there are other significant accounting pronouncements which have had or will have a material impact on the Company’s consolidated financial statements.

 

Note 3. Notes payable

 

During the three month period ended March 31, 2024, the Company reported the following activity in notes and accrued interest:

 

Notes Payable on March 31, 2024 and December 31, 2023 are as follows:

Schedule of Notes Payable 

		March 31, 2024				December 31, 2023
Promissory note			231,478				231,478
Promissory note issued in the first quarter of 2019. The note accrues interest at 6% and matured in February 2020. This note is in default.		$	231,478			$	231,478
Promissory note issued in 2019 for the settlement of debt in the same amount and matured in 2021. Lender earns interest at 15%. This note was modified in November 2022, extending maturity to September 2023. This note is in default.			150,000				150,000
Promissory note issued in 2022 and matured in July 2023. Lender earns interest at 6%. This note is in default.			65,000				65,000
Promissory note issued in 2022 and matured in July 2023. Lender earns interest at 6%. The holder of the note is a former Director and the former Chief Executive Officer of the Company. This note is in default.			200,000				200,000
Promissory note issued in 2022 and matured in December 2023. The lender earns interest at 7.75%. This note is in default.			50,000				50,000
Promissory note issued in March 2023 and matured in May 2023. The lender earns interest at 8%. This note was issued to H. Louis Salomonsky, a Director of the Company. This note is in default.			100,000				100,000
Promissory note issued in March 2023 and matured in June 2023.The lender earns interest at 8%. This note is in default.			50,000				50,000
Promissory note issued in April 2023 and matured in May 2023. The lender earns interest at 18%. This note is in default.			250,000				250,000
Promissory note issued in June 2023 and matures in June 2024. The lender earns interest at 8%.			15,000				15,000
Promissory note issued in July 2023 and matures in July 2025. The lender earns interest at 8.5%. This note was issued to Global Reverb Corporation, a related party of which Noreen Griffin is the sole beneficial owner.			7,500				7,500
Promissory note issued in November 2023 and matures in August 2024. Lender earns interest at 22.0% and is convertible into shares of common stock.			124,424				103,898
		$	1,243,402			$	1,222,876

 

At March 31, 2024 and December 31, 2023, the Company had accrued $182,441 and $146,690, respectively, in unpaid interest on notes payable.

 

14

 

4. Capital Structure – Common Stock and Stock Purchase Warrants

 

Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.

 

Stock Warrants

 

During the three months ended March 31, 2024 and March 31, 2023, no warrants were issued, exercised or modified.

 

The following is a summary of outstanding common stock warrants as of March 31, 2024.

Schedule of Outstanding Common Stock Warrants 

Expiration Date		Number of Shares				Exercise Price				Remaining Life (years)
Third Quarter 2028			3,000			$	70				4.50
Second Quarter 2032			28,995			$	10 - 70				8.25
			31,995			$	10 - 70

 

Following is a summary of stock warrant activity for the three months ended March 31, 2024:

Schedule of Stock Outstanding Warrants Activity 

		Number of Shares				Exercise Price				Weighted Average Price
Warrants as of December 31, 2023			31,995			$	10 - 70			$	56.49
Issued			-			$	-			$	-
Expired and forfeited			-			$	-			$	-
Exercised			-			$	-			$	-
Warrants as of March 31, 2023			31,995			$	10 - 70			$	56.49

 

5. Income Taxes – Results of Operations

 

There was no income tax expense reflected in the results of operations for the periods ended March 31, 2024 and 2023 because the Company has significant net loss operating carryforwards available to offset the potential tax liabilities. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year but are not consistent from year to year.

 

For U.S. federal purposes the corporate statutory income tax rate was 21%, for 2024 and 2023 tax years. The Company has recognized no tax benefit for the losses generated for the periods through March 31, 2024.

 

ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided.

 

6. Subsequent Events

 

Management of the Company has performed a review of events and transactions occurring after the condensed consolidated balance sheet date to determine if there were any such events or transactions requiring adjustment to or disclosure in the accompanying condensed consolidated financial statements and has noted none.

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

 

FORWARD-LOOKING STATEMENTS AND ASSOCIATED RISKS

 

The following management’s discussion and analysis of financial condition and results of operations provides information that management believes is relevant to an assessment and understanding of our plans and financial condition. The following financial information is derived from our condensed consolidated financial statements and should be read in conjunction with such condensed consolidated financial statements and notes thereto and set forth elsewhere herein.

 

Use of Terms

 

Except as otherwise indicated by the context and for the purposes of this report only, references in this report to “we,” “us,” “our” and the “Company” refer to Biostax Corp. a Florida corporation and its consolidated subsidiaries.

 

FORWARD-LOOKING STATEMENTS AND ASSOCIATED RISKS

 

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. This report contains certain forward-looking statements that are based on the beliefs of management as well as assumptions made by and currently available to management. The statements contained in this report relating to matters that are not historical facts are forward-looking statements that involve risks and uncertainties, including, but not limited to, future demand for our products and services, the successful commercialization of our products, general domestic and global economic conditions, government and environmental conditions and regulations, competition and customer strategies, changes in our business strategy or development plans, capital deployment, business disruptions, including those by fires, raw material supplies, environmental regulations, and other risks and uncertainties, certain of which are beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those forward-looking statements. For further discussion of certain of the matters described above see the Cautionary Note Regarding Forward-Looking Statements included in our 2023 Annual Report on Form 10-K/A.

 

Undue reliance should not be placed on our forward-looking statements. Except as required by law, we disclaim an obligation to update any factors or to publicly announce the results of any revisions to any of the forward-looking statements contained in this quarterly report on Form 10-Q to reflect new information, future events, or other developments. The following discussion and analysis should be read in conjunction with the accompanying condensed consolidated financial statements and notes thereto appearing elsewhere in this Form 10-Q.

 

Forward-looking statements can be identified by words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “will,” “would,” “could,” “can,” “may,” and similar terms. Forward-looking statements are not a guarantee of future performance and the Company’s actual results may differ significantly from the results discussed in the forward-looking statements. Each of the terms the “Company”, “we”, “us” or “our” as used herein refers collectively to Biostax Corp and its subsidiaries, unless otherwise stated.

 

COMPANY OVERVIEW

 

Biostax Corp. is a Florida corporation trading on the OTC-Pink. The Company is a drug development and commercialization company. We identify, evaluate, and seek to acquire technologies in the medical device and drug development sectors with the intent to further develop them and move them to commercialization.

 

Our strategy has been limited due to lack of capital. Management is seeking to secure new investment capital with which to continue to pursue the Company’s strategy. There is no guarantee that the Company will be successful in securing additional capital.

 

GOING CONCERN

 

As of March 31, 2024, the Company had $2,098 in cash on hand, negative working capital of $4,864,722 and accumulated stockholders’ deficit of $385,668,216. For the three months ended March 31, 2024, the Company reported a net loss attributable to common shareholders of $337,076. For the three months ended March 31, 2023, the Company reported a net loss attributable to common shareholders of $416,117.

 

Historically the Company has relied on the funding of operations through private equity financing and management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its current or future product candidates as they become available and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources.

 

 

Working capital at March 31, 2023 is not sufficient to meet the cash requirements to fund planned operations through the next twelve months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

 

Management is continuing to develop strategies to re-capitalize the Company and position it for future growth. Key steps to this process include:

 

	●	Improve the condition of the balance sheet via license arrangements and capital infusions.
	●	Identify and acquire late-stage assets for commercialization.
	●	Build out operational infrastructure to generate revenue opportunities to grow shareholder value.

 

There can be no guaranties that the Company will be successful in securing adequate capital to continue operations and in identifying and acquiring assets for future development.

 

If the Company is unable to secure new working capital, other alternatives strategies will be required.

 

Historically, the Company has been able to acquire and develop assets, spin them out and retain both an equity stake and royalties and milestone payments. In so doing, the Company has acted as an incubator for late-stage drug development. Management believes that this strategy can continue to be successful. At this time, the Company is reviewing several opportunities which it may pursue as soon as funding is available. At present no definitive actions have been taken.

 

There can be no guarantees that the Company will be successful in:

 

	●	Executing its restructuring plan
	●	Securing adequate capital to continue operations.
	●	Identifying and acquiring assets for future development.

 

RESULTS FROM OF THE THREE MONTHS ENDED MARCH 31, 2023

COMPARED TO THE THREE MONTHS ENDED MARCH 31, 2022

 

Revenues

 

We had no revenues from operations for the three months ended March 31, 2024 and 2023.

 

Operating Expenses

 

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses for the three months ended March 31, 2024 and 2023 were as follows:

 

		For the three months ended March 31
		2024				2023
Selling, general and administrative		$	254,250			$	207,517
Increase (decrease) from prior year		$	46,733			$	25,901
Percent increase (decrease) from prior year			23	%			14	%

 

During the three months ended March 31, 2024, the Company has focused on the negotiation and finalization of certain licensing transactions and business development opportunities.

 

For the three months ended March 31, 2024 and 2023, selling, general and administrative expenses were made up as follows:

 

		For the three months ended March 31
		2024				2023
Shareholder and investor relations		$	3,499			$	6,016
Professional fees and consulting costs			12,005				56,741
Consulting fees with related parties			221,155				107,950
Board fees			12,000				30,000
Other expenses			5,591				6,810
Total		$	254,250			$	207,517
Increase from prior period		$	46,733			$	25,901

 

 

The increase in selling, general and administrative expenses for the three months ended March 31, 2024 is primarily driven by consulting fees paid to the management team, offset by a reduction costs in all other areas.

 

Research and Development Expenses

 

R&D expenses and related percentages for the three months ended March 31, 2024 and 2023 were as follows:

 

		For the three months ended March 31,
		2024				2023
Research and development		$	11,077			$	180,924
Increase/(decrease) from prior year		$	(169,847	)		$	180,924
Percent increase/(decrease) from prior year			(94	)%			100	)%

 

Research and development expense for the three months ended March 31, 2024 was $11,077, compared to $180,924 incurred in the same period in 2023.

 

The research and development expenses for the three months ended March 31, 2024 reflects amounts accrued for interest and penalties pursuant to the license of intangible assets from TaiwanJ Pharmaceuticals.

 

Interest Expense

 

Interest expense for the three months ended March 31, 2024 and 2023 were as follows (dollar amounts in thousands):

 

		For the three months ended March 31,
		2024				2023
Interest expense		$	71,749			$	14,299
Increase (decrease) from prior year		$	57,450			$	(77,885	)
Percentage Decrease from prior year			402	%			(84	)%

 

Interest expense is comprised of accrued interest on notes payable owed by the Company, unpaid amounts owed to consultants and the amortization of the discount related to derivate instruments underlying notes payable. The increase year over year reflects the increase in outstanding notes and consulting payments as well as the increase in interest rates.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Overview

 

Liquidity is measured by our ability to secure enough cash to meet our contractual and operating needs as they arise. The Company does not anticipate generating sufficient cash flows from our operations to fund the next twelve months. We had cash on hand of $2,098 at March 31, 2024, compared to $29,785 at December 31, 2023.

 

 

Summary of Cash Flows

 

		For the three months ended March 31
		2024				2023
Net cash used in operating activities		$	(53,839	)		$	(265,498	)
Net cash provided by financing activities			26,151				150,000
Net decrease in cash and cash equivalents		$	(27,688	)		$	(115,498	)

 

Net cash used in operating activities was $53,839 for the three months ended March 31, 2024, compared to $265,498 for the corresponding period in 2023. The use of cash in these periods resulted primarily from our losses from operations, as adjusted for changes in our working capital accounts. For the period ending March 31, 2023, the net loss of $2,566,500 was adjusted by $2,282,750 loss on impairment in common stock.

 

The Company had no cash used or provided from investing activities during the three-month periods ended March 31, 2024 and 2023.

 

For the three months ended March 31, 2024, the Company received $26,151 in financing activities from issued notes payable.

 

The Company does not expect to generate revenues in the foreseeable future. If the Company is unable to raise additional working capital to meet its operating obligations and expenditures, the Company will be required to modify its business plan.

 

CONTRACTUAL OBLIGATIONS

 

Promissory Notes

 

The notes payable on the Company’s Condensed Consolidated Balance Sheet above contains, at March 31, 2024, certain promissory notes on which the Company was in arrears on payment of principal as follows:

 

●	$231,478 in promissory notes issued in 2019. The notes accrue interest at 6% and matured in 2020.
●	$150,000 promissory note issued in 2023. The note accrued interest at 8% and matured in 2023.
●	$265,000 in promissory notes issued in 2022. The notes accrued interest at 6% and matured in 2023.
●	$150,000 in promissory notes issued in 2023. The notes accrued interest at 8% and matured in 2023.
●	$50,000 in promissory notes issued in 2023. The notes accrued interest at 7.75% and matured in 2023.
●	$250,000 promissory note issued in 2023. The note accrued interest at 18% and matured in 2023.

 

Please refer to Note 3 to the Condensed Consolidated Financial Statements of Part I Item 1, which is incorporated by reference, for additional details regarding these promissory notes.

 

OFF BALANCE SHEET ARRANGEMENTS

 

During the three months ended March 31, 2024 and 2023, the Company did not engage in any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial conditions, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s board of directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results.

 

Fair Value of Financial Instruments

 

In accordance with the reporting requirements of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the condensed consolidated financial statements when the fair value is different than the carrying value of those financial instruments.

 

Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.

 

 

Research and Development Costs

 

Research and development costs are charged to expense as incurred and are typically comprised of expenses associated with advancing the commercialization of our technologies.

 

Income Taxes

 

The Company follows ASC Topic 740, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

 

Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration

 

The Company measures and recognizes compensation expense for share-based awards based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement.

 

The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “Compensation-Stock Compensation.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.

 

Recent Accounting Standards

 

The Company has reviewed the accounting pronouncements issued by the FASB during the three months ended March 31, 2024. Applicable pronouncements will be adopted by the Company in accordance with the accounting guidance and definition. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

 

Management does not believe there are other significant accounting pronouncements which have had or will have a material impact on the Company’s condensed consolidated financial statements.

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not Applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the period covered by this report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based on this evaluation, the principal executive officer and the principal financial officer concluded that, because of the weakness in internal control over financial reporting described below, our disclosure controls and procedures are ineffective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

 

Management assessed the effectiveness of our internal control over financial reporting using the framework set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based upon this assessment, management concluded that our internal control over financial reporting was not effective. The reportable conditions and material weakness relate to a limited segregation of duties and lack of an audit committee. The limited segregation of duties within the Company and the lack of an audit committee are due to the small number of employees. Management has determined that this control deficiency constitutes a material weakness. This material weakness could result in material misstatements of significant accounts and disclosures that would result in a material misstatement to our interim or annual financial statements that would not be prevented or detected. In addition, due to limited staffing, we are not always able to detect minor errors or omissions in reporting.

 

Going forward, management anticipates that additional staff will be necessary to remediate these weaknesses, as well as other planned improvements. Additional staff will enable us to document and apply transactional and periodic controls procedures, permit a better review and approval process and improve quality of financial reporting. However, the potential addition of new staff is contingent on obtaining additional financing, and there is no assurance that we will be able to do so.

 

Limitations on the Effectiveness of Disclosure Controls and Procedures and Internal Control Over Financial Reporting

 

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings which arise during the ordinary course of business.

 

ITEM 1A. RISK FACTORS

 

Not applicable.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

During the quarter ended March 31, 2024, the Company issued the following securities:

 

The Company issued 81,086 shares of common stock to Ira Gaines, pursuant to the Second Amendment to Promissory Note issued on October 1, 2019.

 

We did not repurchase any shares of our common stock during the three months ended March 31, 2024.

 

The issuances of shares of common stock described above will not be registered under the Securities Act of 1933, as amended, or the Securities Act, in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act, and/or Regulation D promulgated thereunder.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

Refer to Note 3 to the Condensed Consolidated Financial Statements of Part I Item 1, which is incorporated by reference, for additional details. The notes payable on the Company’s Condensed Consolidated Balance Sheet above contains, at March 31, 2024, certain promissory notes on which the Company was in arrears on payment of principal as follows:

 

●	$231,478 in promissory notes issued in 2019. The notes accrue interest at 6% and matured in 2020.
●	$150,000 promissory note issued in 2023. The note accrued interest at 8% and matured in 2023.
●	$265,000 in promissory notes issued in 2022. The notes accrued interest at 6% and matured in 2023.
●	$150,000 in promissory notes issued in 2023. The notes accrued interest at 8% and matured in 2023.
●	$50,000 in promissory notes issued in 2023. The notes accrued interest at 7.75% and matured in 2023.
●	$250,000 promissory note issued in 2023. The note accrued interest at 18% and matured in 2023.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

None.

 

ITEM 5. OTHER INFORMATION

 

None.

 

 

ITEM 6. EXHIBITS

 

The following exhibits are filed with this Quarterly Report:

 

Exhibit		Description
3.1		Articles of Incorporation and Amendments Thereto (incorporated by reference to Exhibit 3.1 to Amendment No. 1 to Form 10 filed with the SEC on June 7, 2013).
3.2		Bylaws (incorporated by reference to Exhibit 3.2 to Amendment No. 1 to the Form 10 filed with the SEC on June 7, 2013).
10.1		Intellectual Property License Agreement, dated September 30, 2022, between Immune Therapeutics, Inc. and TaiwainJ Pharmaceuticals Co. Ltd. (incorporated by reference to Form 8-K filed on October 12, 2022).***
31.1*		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification of Chief Executive Officer pursuant to 18 United States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification of Chief Financial Officer pursuant to 18 United States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Taxonomy Extension Schema
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase
104*		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith

** Furnished herewith

*** Portions of this exhibit have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv) because the Company has determined that the information is not material and is the type that the Company treats as private or confidential.

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Biostax Corp
Date: May 20, 2024	By:	/s/ Noreen Griffin
	Name:	Noreen Griffin
	Title:	Chief Executive Officer

 

	Biostax Corp
Date: May 20, 2024	By:	/s/ Glen Farmer
	Name:	Glen Farmer
	Title:	Chief Financial Officer

 

 

 

Exhibit 31.1

 

CERTIFICATION

 

I, Noreen Griffin, certify that:

 

1.	I have reviewed this quarterly report on Form 10-Q of Biostax Corp;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 20, 2024	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer
		(Principal Executive Officer)

 

 

 

Exhibit 31.2

 

CERTIFICATION

 

I, Glen Farmer, certify that:

 

1.	I have reviewed this quarterly report on Form 10-Q of Biostax Corp;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 20, 2024	By:	/s/ Glen Farmer
		Glen Farmer
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

 

 

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of Biostax Corp (the “Company”) on Form 10-Q for the quarter ending March 31, 2024 as filed with the Securities and Exchange Commission (the “Report”), I , Noreen Griffin, Chief Executive Officer (Principal Executive Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

Date: May 20, 2024	By:	/s/ Noreen Griffin
		Noreen Griffin
		Chief Executive Officer
		(Principal Executive Officer)

 

 

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the quarterly report of Biostax Corp (the “Company”) on Form 10-Q for the quarter ending March 31, 2023 as filed with the Securities and Exchange Commission (the “Report”), I , Glen Farmer, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

 

Date: May 20, 2024	By:	/s/ Glen Farmer
		Glen Farmer
		Chief Financial Officer (Principal Financial and Accounting Officer)

 

v3.24.1.1.u2

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 20, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	000-54933
Entity Registrant Name	BIOSTAX CORP
Entity Central Index Key	0001559356
Entity Tax Identification Number	59-3226705
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	2431 Aloma Ave.
Entity Address, Address Line Two	Suite 124
Entity Address, City or Town	Winter Park
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32792
City Area Code	888
Local Phone Number	613-8802
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		83,711,316

v3.24.1.1.u2

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 2,098	$ 29,785
Total current assets	2,098	29,785
Deposits	5,500	5,500
Total Assets	7,598	35,285
Current Liabilities:
Accounts payable	1,352,465	1,350,984
Accrued payroll	336,002	336,002
Notes payable, net of debt discount	1,243,402	1,222,876
Due to related parties	1,310,147	1,069,594
Accrued interest	182,440	152,315
Accrued liabilities	136,057	136,057
License fees payable	306,307	295,230
Total current liabilities	4,866,820	4,563,057
Total Liabilities	4,866,820	4,563,057
Stockholders’ Deficit:
Common stock – par value $0.0001; 750,000,000 and 750,000,000 shares authorized, respectively; 83,711,316 and 83,243,079 shares issued and outstanding respectively	8,374	8,366
Additional paid in capital	380,800,619	380,795,003
Accumulated deficit	(385,668,216)	(385,331,140)
Total stockholders’ deficit	(4,859,222)	(4,527,772)
Total Liabilities and Stockholders’ Deficit	$ 7,598	$ 35,285

v3.24.1.1.u2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	83,711,316	83,243,079
Common stock, shares outstanding	83,711,316	83,243,079

v3.24.1.1.u2

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Selling, general and administrative	$ 254,250	$ 207,517
Research and development expense	11,077	180,924
Depreciation and amortization expense		13,377
Total operating expenses	265,327	401,818
Loss from operations	(265,327)	(401,818)
Other (expense) income:
Interest expense	(71,749)	(14,299)
Total other (expense) income	(71,749)	(14,299)
Net loss	$ (337,076)	$ (416,117)
Basic (loss) income per share attributable to common shareholders	$ (0.00)	$ (0.00)
Diluted (loss) income per share to common shareholders	$ (0.00)	$ (0.00)
Basic weighted average number of shares outstanding	83,711,316	83,243,079
Diluted weighted average number of shares outstanding	85,782,403	83,243,079

v3.24.1.1.u2

Consolidated Statements of Stockholders' Equity/(Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock to be Issued [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 8,305	$ 380,436,432	$ 10,303	$ (382,968,494)	$ (2,513,454)
Balance, shares at Dec. 31, 2022	83,045,857
Issuance of common stock for extension of patent and license agreement	$ 25	149,975			150,000
Issuance of common stock for extension of patent and license agreement, shares	250,000
Net loss				(416,117)	(416,117)
Balance at Mar. 31, 2023	$ 8,330	380,586,407	10,303	(383,384,611)	(2,779,571)
Balance, shares at Mar. 31, 2023	83,295,857
Balance at Dec. 31, 2023	$ 8,366	380,795,002		(385,331,141)	(4,527,772)
Balance, shares at Dec. 31, 2023	83,657,853
Net loss				(337,076)	(337,076)
Issuance of common stock upon conversion of notes and obligations	$ 8	5,617			5,626
Issuance of common stock upon conversion of notes and obligations, shares	81,086
Balance at Mar. 31, 2024	$ 8,374	$ 380,800,619		$ (385,668,217)	$ (4,859,222)
Balance, shares at Mar. 31, 2024	83,738,939

v3.24.1.1.u2

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (337,076)	$ (416,117)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Loss on impairment on investment in common stock
Amortization of intangibles		13,377
Common stock issued for the extension of patent and license agreement		150,000
Changes in operating assets and liabilities:
Deposits		38,116
Accounts payable	1,482
License fees payable	11,077	(127,305)
Accrued payroll
Accrued interest	30,125	14,299
Accrued liabilities		15,000
Due to related parties	240,553	47,132
Net cash used in operating activities	(53,839)	(265,498)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of notes payable	26,151	150,000
Net cash provided by financing activities	26,151	150,000
Decrease in cash	(27,688)	(115,498)
Cash and cash equivalents, beginning of year	29,785	150,491
Cash and cash equivalents, end of year	$ 2,098	$ 34,993

v3.24.1.1.u2

Company Overview	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Company Overview	1. Company Overview   Biostax Corp. (the “Company” or “BTAX”) is a Florida corporation trading on the OTC-Pink. The Company is a drug development and commercialization company. We identify, evaluate, and seek to acquire technologies in the medical device and drug development sectors with the intent to further develop them and move them to commercialization. On February 28, 2023, we received a written consent from a majority of our outstanding shareholders to change the name of our Company to “Biostax Corp.” On March 27, 2023, we filed a definitive information statement on Schedule 14C and mailed the information statement to shareholders on record as of the date of the filing. We filed our name change amendment with the Secretary of State of Florida on October 5, 2023 and our new Company name and trading symbol (BTAX) became effective on October 20, 2023.   Going Concern   As of March 31, 2024, the Company had $2,098 in cash on hand, negative working capital of $4,864,722 and accumulated stockholders’ deficit of $385,668,216. For the three months ended March 31, 2024, the Company reported a net loss attributable to common shareholders of $337,076. For the three months ended March 31, 2023, the Company reported a net loss attributable to common shareholders of $416,117.   Historically the Company has relied on the funding of operations through private equity financing and management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its current or future product candidates as they become available and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources.   Working capital at March 31, 2024 is not sufficient to meet the cash requirements to fund planned operations through the next twelve months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.   Management is continuing to develop strategies to re-capitalize the Company and position it for future growth. Key steps to this process include:     ● Improve the condition of the balance sheet via license arrangements and capital infusions.   ● Identify and acquire late-stage assets for commercialization.   ● Build out operational infrastructure to generate revenue opportunities to grow shareholder value.   There can be no guaranties that the Company will be successful in securing adequate capital to continue operations and in identifying and acquiring assets for future development.     If the Company is unable to secure new working capital, other alternatives strategies will be required.   Historically, the Company’s strategy has been to acquire and develop assets; potentially spin them out and retain both an equity stake and royalties and milestone payments. In so doing, the Company would act as an incubator for late-stage drug development. Management believes that this strategy can be successful. At this time, the Company is reviewing several opportunities which it may pursue as soon as funding is available. At present, no definitive action has been taken.   There can be no guarantees that the Company will be successful in:     ● Executing its restructuring plan;   ● Securing adequate capital to continue operations; or   ● Identifying and acquiring assets for future development.   Company History   The Company was initially incorporated in Florida on December 2, 1993, as Resort Clubs International, Inc. (“Resort Clubs”). It was formed to manage and market golf course properties in resort markets throughout the United States. Galliano International Ltd. (“Galliano”) was incorporated in Delaware on May 27, 1998 and began trading in November 1999 through the filing of a 15C-211. On November 10, 2004, Galliano merged with Resort Clubs. Resort Clubs was the surviving corporation. On August 23, 2010, Resort Clubs changed its name to pH Environmental Inc. (“pH Environmental”). On April 23, 2012, pH Environmental completed a name change to TNI BioTech, Inc., and on April 24, 2012, we executed a share exchange agreement for the acquisition of all the outstanding shares of TNI BioTech IP, Inc. On September 4, 2014, a majority of our shareholders approved an amendment to our Amended and Restated Articles of Incorporation, as amended, to change our name to Immune Therapeutics, Inc. On February 28, 2023, we received a written consent from a majority of our outstanding shareholders to change the name of our Company to “Biostax Corp.” On March 27, 2023, we filed a definitive information statement on Schedule 14C and mailed the information statement to shareholders on record as of the date of the filing. We filed our name change amendment with the Secretary of State of Florida on October 5, 2023 and our new Company name and trading symbol (BTAX) became effective on October 20, 2023

v3.24.1.1.u2

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies   Basis of Presentation   The condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the consolidated financial position and consolidated results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These condensed, consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2023 (including the notes thereto) set forth in the Company’s Annual Report on Form 10- K/A for that period.   Use of Estimates   The preparation of the Company’s condensed, consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed, consolidated financial statements and accompanying notes. Actual results could differ from such estimates.     Cash, Cash Equivalents, and Short-Term Investments   The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value. At March 31, 2024 and December 31, 2023, the Company had cash and cash equivalents of $2,098 and $29,785, respectively.   Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000.   Segment and Geographic Information   Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.   Fair Value of Financial Instruments   In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments.   Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.   Research and Development Costs   Research and development costs are charged to expense as incurred and are typically comprised of expenses associated with advancing the commercialization of our technologies. The Company incurred $11,077 of research and development costs during the three months ended March 31, 2024, which solely represents interest and late fees related to the Company’s license agreement with TaiwanJ Pharmaceuticals. The Company inclurred $180,924 of research and development costs during the three months ended March 31, 2023 which includes legal fees related to the maintenance and prosecution of licensed and owned intellectual property as well as the fair value of common stock issued to extend the payment terms of the Company’s license agreement with TaiwanJ Pharmaceuticals.   Income Taxes   The Company follows ASC Topic 740, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.     The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.   At the date of adoption, and as of March 31, 2024 and 2023, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of March 31, 2024, and 2023, the Company does not have any interest or penalties related to uncertain tax positions.   Stock-Based Compensation and Issuance of Common Stock for Non-Cash Consideration   The Company measures and recognizes compensation expense for share-based awards based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement.   The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “Compensation-Stock Compensation.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.   The Company did not issue any stock-based compensation awards during the three months ended March 31, 2024 and 2023.   Net Income (Loss) per Share   For the three months ended March 31, 2024, basic and diluted net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents.     For the three months ended March 31, 2024, diluted income per share was calculated by dividing the net income by the weighted-average number of common shares outstanding for the period determined using the treasury-stock method. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share for the periods ended March 31, 2024 and 2023 are as follows:   Schedule of Basic and Diluted Earnings per Share     March 31, 2024     March 31, 2023       Three Months ended       March 31, 2024     March 31, 2023   Basic EPS                 Income (loss) available to common shareholders (Numerator)   $ (337,076 )   $ (416,117 ) Weighted average common shares (Denominator)     83,711,316       83,243,079   Basic EPS   $ (0.00 )   $ (0.00 )                   Diluted EPS                 Income (loss) available to common shareholders (Numerator)   $ (337,076 )   $ (416,117 ) Weighted average common shares (Denominator)     85,782,403       83,243,079   Diluted EPS   $ (0.00 )   $ (0.00 )   Recent Accounting Standards   The Company has reviewed the accounting pronouncements issued by the FASB during the first quarter of 2024. Applicable pronouncements will be adopted by the Company in accordance with the accounting guidance and definition. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.   Management does not believe there are other significant accounting pronouncements which have had or will have a material impact on the Company’s consolidated financial statements.

v3.24.1.1.u2

Notes payable	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Notes payable	Note 3. Notes payable   During the three month period ended March 31, 2024, the Company reported the following activity in notes and accrued interest:   Notes Payable on March 31, 2024 and December 31, 2023 are as follows: Schedule of Notes Payable      March 31, 2024     December 31, 2023                 Promissory note     231,478       231,478   Promissory note issued in the first quarter of 2019. The note accrues interest at 6% and matured in February 2020. This note is in default.   $ 231,478     $ 231,478                     Promissory note issued in 2019 for the settlement of debt in the same amount and matured in 2021. Lender earns interest at 15%. This note was modified in November 2022, extending maturity to September 2023. This note is in default.     150,000       150,000                     Promissory note issued in 2022 and matured in July 2023. Lender earns interest at 6%. This note is in default.     65,000       65,000                     Promissory note issued in 2022 and matured in July 2023. Lender earns interest at 6%. The holder of the note is a former Director and the former Chief Executive Officer of the Company. This note is in default.     200,000       200,000                     Promissory note issued in 2022 and matured in December 2023. The lender earns interest at 7.75%. This note is in default.     50,000       50,000                     Promissory note issued in March 2023 and matured in May 2023. The lender earns interest at 8%. This note was issued to H. Louis Salomonsky, a Director of the Company. This note is in default.     100,000       100,000                     Promissory note issued in March 2023 and matured in June 2023.The lender earns interest at 8%. This note is in default.     50,000       50,000                     Promissory note issued in April 2023 and matured in May 2023. The lender earns interest at 18%. This note is in default.     250,000       250,000                     Promissory note issued in June 2023 and matures in June 2024. The lender earns interest at 8%.     15,000       15,000                     Promissory note issued in July 2023 and matures in July 2025. The lender earns interest at 8.5%. This note was issued to Global Reverb Corporation, a related party of which Noreen Griffin is the sole beneficial owner.     7,500       7,500                     Promissory note issued in November 2023 and matures in August 2024. Lender earns interest at 22.0% and is convertible into shares of common stock.     124,424       103,898                         $ 1,243,402     $ 1,222,876     At March 31, 2024 and December 31, 2023, the Company had accrued $182,441 and $146,690, respectively, in unpaid interest on notes payable.

v3.24.1.1.u2

Capital Structure – Common Stock and Stock Purchase Warrants	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Capital Structure – Common Stock and Stock Purchase Warrants	4. Capital Structure – Common Stock and Stock Purchase Warrants   Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend.   Stock Warrants   During the three months ended March 31, 2024 and March 31, 2023, no warrants were issued, exercised or modified.   The following is a summary of outstanding common stock warrants as of March 31, 2024. Schedule of Outstanding Common Stock Warrants  Expiration Date   Number of Shares     Exercise Price     Remaining Life (years)                       Third Quarter 2028     3,000     $ 70       4.50   Second Quarter 2032     28,995     $ 10 - 70       8.25         31,995     $ 10 - 70             Following is a summary of stock warrant activity for the three months ended March 31, 2024: Schedule of Stock Outstanding Warrants Activity      Number of Shares     Exercise Price     Weighted Average Price   Warrants as of December 31, 2023     31,995     $ 10 - 70     $ 56.49   Issued     -     $ -     $ -   Expired and forfeited     -     $ -     $ -   Exercised     -     $ -     $ -   Warrants as of March 31, 2023     31,995     $ 10 - 70     $ 56.49

v3.24.1.1.u2

Income Taxes – Results of Operations	3 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes – Results of Operations	5. Income Taxes – Results of Operations   There was no income tax expense reflected in the results of operations for the periods ended March 31, 2024 and 2023 because the Company has significant net loss operating carryforwards available to offset the potential tax liabilities. Our tax rate can be affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. It may also be affected by discrete items that may occur in any given year but are not consistent from year to year.   For U.S. federal purposes the corporate statutory income tax rate was 21%, for 2024 and 2023 tax years. The Company has recognized no tax benefit for the losses generated for the periods through March 31, 2024.   ASC Topic 740 requires that a valuation allowance be provided if it is more likely than not that some portion or all a deferred tax asset will not be realized. The Company’s ability to realize the benefit of its deferred tax asset will depend on the generation of future taxable income. Because the Company has yet to recognize revenue, we believe that the full valuation allowance should be provided.

v3.24.1.1.u2

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	6. Subsequent Events   Management of the Company has performed a review of events and transactions occurring after the condensed consolidated balance sheet date to determine if there were any such events or transactions requiring adjustment to or disclosure in the accompanying condensed consolidated financial statements and has noted none.

v3.24.1.1.u2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation   The condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the consolidated financial position and consolidated results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These condensed, consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2023 (including the notes thereto) set forth in the Company’s Annual Report on Form 10- K/A for that period.
Use of Estimates	Use of Estimates   The preparation of the Company’s condensed, consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed, consolidated financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-Term Investments	Cash, Cash Equivalents, and Short-Term Investments   The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value. At March 31, 2024 and December 31, 2023, the Company had cash and cash equivalents of $2,098 and $29,785, respectively.
Concentration of Credit Risk	Concentration of Credit Risk   Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $250,000.
Segment and Geographic Information	Segment and Geographic Information   Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments   In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments.   Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.
Research and Development Costs	Research and Development Costs   Research and development costs are charged to expense as incurred and are typically comprised of expenses associated with advancing the commercialization of our technologies. The Company incurred $11,077 of research and development costs during the three months ended March 31, 2024, which solely represents interest and late fees related to the Company’s license agreement with TaiwanJ Pharmaceuticals. The Company inclurred $180,924 of research and development costs during the three months ended March 31, 2023 which includes legal fees related to the maintenance and prosecution of licensed and owned intellectual property as well as the fair value of common stock issued to extend the payment terms of the Company’s license agreement with TaiwanJ Pharmaceuticals.
Income Taxes	Income Taxes   The Company follows ASC Topic 740, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.     The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.   At the date of adoption, and as of March 31, 2024 and 2023, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of March 31, 2024, and 2023, the Company does not have any interest or penalties related to uncertain tax positions.
Stock-Based Compensation and Issuance of Common Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Common Stock for Non-Cash Consideration   The Company measures and recognizes compensation expense for share-based awards based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement.   The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “Compensation-Stock Compensation.” The measurement date for the fair value of the equity instruments issued is determined at the earlier of (i) the date at which a commitment for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor’s performance is complete.   The Company did not issue any stock-based compensation awards during the three months ended March 31, 2024 and 2023.
Net Income (Loss) per Share	Net Income (Loss) per Share   For the three months ended March 31, 2024, basic and diluted net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents.     For the three months ended March 31, 2024, diluted income per share was calculated by dividing the net income by the weighted-average number of common shares outstanding for the period determined using the treasury-stock method. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share for the periods ended March 31, 2024 and 2023 are as follows:   Schedule of Basic and Diluted Earnings per Share     March 31, 2024     March 31, 2023       Three Months ended       March 31, 2024     March 31, 2023   Basic EPS                 Income (loss) available to common shareholders (Numerator)   $ (337,076 )   $ (416,117 ) Weighted average common shares (Denominator)     83,711,316       83,243,079   Basic EPS   $ (0.00 )   $ (0.00 )                   Diluted EPS                 Income (loss) available to common shareholders (Numerator)   $ (337,076 )   $ (416,117 ) Weighted average common shares (Denominator)     85,782,403       83,243,079   Diluted EPS   $ (0.00 )   $ (0.00 )
Recent Accounting Standards	Recent Accounting Standards   The Company has reviewed the accounting pronouncements issued by the FASB during the first quarter of 2024. Applicable pronouncements will be adopted by the Company in accordance with the accounting guidance and definition. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.   Management does not believe there are other significant accounting pronouncements which have had or will have a material impact on the Company’s consolidated financial statements.

v3.24.1.1.u2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of Basic and Diluted Earnings per Share	Schedule of Basic and Diluted Earnings per Share     March 31, 2024     March 31, 2023       Three Months ended       March 31, 2024     March 31, 2023   Basic EPS                 Income (loss) available to common shareholders (Numerator)   $ (337,076 )   $ (416,117 ) Weighted average common shares (Denominator)     83,711,316       83,243,079   Basic EPS   $ (0.00 )   $ (0.00 )                   Diluted EPS                 Income (loss) available to common shareholders (Numerator)   $ (337,076 )   $ (416,117 ) Weighted average common shares (Denominator)     85,782,403       83,243,079   Diluted EPS   $ (0.00 )   $ (0.00 )

v3.24.1.1.u2

Notes payable (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes Payable on March 31, 2024 and December 31, 2023 are as follows: Schedule of Notes Payable      March 31, 2024     December 31, 2023                 Promissory note     231,478       231,478   Promissory note issued in the first quarter of 2019. The note accrues interest at 6% and matured in February 2020. This note is in default.   $ 231,478     $ 231,478                     Promissory note issued in 2019 for the settlement of debt in the same amount and matured in 2021. Lender earns interest at 15%. This note was modified in November 2022, extending maturity to September 2023. This note is in default.     150,000       150,000                     Promissory note issued in 2022 and matured in July 2023. Lender earns interest at 6%. This note is in default.     65,000       65,000                     Promissory note issued in 2022 and matured in July 2023. Lender earns interest at 6%. The holder of the note is a former Director and the former Chief Executive Officer of the Company. This note is in default.     200,000       200,000                     Promissory note issued in 2022 and matured in December 2023. The lender earns interest at 7.75%. This note is in default.     50,000       50,000                     Promissory note issued in March 2023 and matured in May 2023. The lender earns interest at 8%. This note was issued to H. Louis Salomonsky, a Director of the Company. This note is in default.     100,000       100,000                     Promissory note issued in March 2023 and matured in June 2023.The lender earns interest at 8%. This note is in default.     50,000       50,000                     Promissory note issued in April 2023 and matured in May 2023. The lender earns interest at 18%. This note is in default.     250,000       250,000                     Promissory note issued in June 2023 and matures in June 2024. The lender earns interest at 8%.     15,000       15,000                     Promissory note issued in July 2023 and matures in July 2025. The lender earns interest at 8.5%. This note was issued to Global Reverb Corporation, a related party of which Noreen Griffin is the sole beneficial owner.     7,500       7,500                     Promissory note issued in November 2023 and matures in August 2024. Lender earns interest at 22.0% and is convertible into shares of common stock.     124,424       103,898                         $ 1,243,402     $ 1,222,876

v3.24.1.1.u2

Capital Structure – Common Stock and Stock Purchase Warrants (Tables)	3 Months Ended
	Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Outstanding Common Stock Warrants	The following is a summary of outstanding common stock warrants as of March 31, 2024. Schedule of Outstanding Common Stock Warrants  Expiration Date   Number of Shares     Exercise Price     Remaining Life (years)                       Third Quarter 2028     3,000     $ 70       4.50   Second Quarter 2032     28,995     $ 10 - 70       8.25         31,995     $ 10 - 70
Schedule of Stock Outstanding Warrants Activity	Following is a summary of stock warrant activity for the three months ended March 31, 2024: Schedule of Stock Outstanding Warrants Activity      Number of Shares     Exercise Price     Weighted Average Price   Warrants as of December 31, 2023     31,995     $ 10 - 70     $ 56.49   Issued     -     $ -     $ -   Expired and forfeited     -     $ -     $ -   Exercised     -     $ -     $ -   Warrants as of March 31, 2023     31,995     $ 10 - 70     $ 56.49

v3.24.1.1.u2

Company Overview (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash on hand	$ 2,098		$ 29,785
Working capital	4,864,722
Accumulated deficit	385,668,216		$ 385,331,140
Net loss attributable to common stockholders	$ 337,076	$ 416,117

v3.24.1.1.u2

Schedule of Basic and Diluted Earnings per Share (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accounting Policies [Abstract]
Income (loss) available to common shareholders (Numerator)	$ (337,076)	$ (416,117)
Weighted average common shares (Denominator)	83,711,316	83,243,079
Basic EPS	$ (0.00)	$ (0.00)
Income (loss) available to common shareholders (Numerator)	$ (337,076)	$ (416,117)
Weighted average common shares (Denominator)	85,782,403	83,243,079
Diluted EPS	$ (0.00)	$ (0.00)

v3.24.1.1.u2

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Accounting Policies [Abstract]
Cash and cash equivalents	$ 2,098		$ 29,785
Cash at federal deposit	250,000
Research and development costs	11,077	$ 180,924
Interest or penalties related to uncertain tax position	0	0
Stock-based compensation	$ 0	$ 0

v3.24.1.1.u2

Schedule of Notes Payable (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Notes payable	$ 1,243,402	$ 1,222,876
Notes Payable [Member]
Short-Term Debt [Line Items]
Notes payable	231,478	231,478
Notes Payable One [Member]
Short-Term Debt [Line Items]
Notes payable	150,000	150,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Notes payable	65,000	65,000
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Notes payable	200,000	200,000
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Notes payable	50,000	50,000
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Notes payable	100,000	100,000
Notes Payable Six [Member]
Short-Term Debt [Line Items]
Notes payable	50,000	50,000
Notes Payable Seven [Member]
Short-Term Debt [Line Items]
Notes payable	250,000	250,000
Notes Payable Eight [Member]
Short-Term Debt [Line Items]
Notes payable	15,000	15,000
Notes Payable Nine [Member]
Short-Term Debt [Line Items]
Notes payable	7,500	7,500
Notes Payable Ten [Member]
Short-Term Debt [Line Items]
Notes payable	$ 124,424	$ 103,898

v3.24.1.1.u2

Schedule of Notes Payable (Details) (Parenthetical)	1 Months Ended					3 Months Ended	12 Months Ended
	Nov. 30, 2023	Jul. 31, 2023	Jun. 30, 2023	Apr. 30, 2023	Mar. 31, 2023	Mar. 31, 2019	Dec. 31, 2022	Dec. 31, 2019
Notes Payable [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum						6.00%
Debt instrument maturity date						February 2020
Notes Payable One [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum								15.00%
Debt instrument maturity date								September 2023
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum							6.00%
Debt instrument maturity date							July 2023
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum							6.00%
Debt instrument maturity date							July 2023
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum							7.75%
Debt instrument maturity date							December 2023
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum					8.00%
Debt instrument maturity date					May 2023
Notes Payable Six [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum					8.00%
Debt instrument maturity date					June 2023
Notes Payable Seven [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum				18.00%
Debt instrument maturity date				May 2023
Notes Payable Eight [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum			8.00%
Debt instrument maturity date			June 2024
Notes Payable Nine [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum		8.50%
Debt instrument maturity date		July 2025
Notes Payable Ten [Member]
Short-Term Debt [Line Items]
Percentage of interest rate per annum	22.00%
Debt instrument maturity date	August 2024

v3.24.1.1.u2

Notes payable (Details Narrative) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Interest payable	$ 182,441	$ 146,690

v3.24.1.1.u2

Schedule of Outstanding Common Stock Warrants (Details)	Mar. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	31,995
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	$ 10
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	$ 70
Third Quarter 2028 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	3,000
Exercise Price	$ 70
Remaining Life (years)	4 years 6 months
Second Quarter 2032 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares | shares	28,995
Remaining Life (years)	8 years 3 months
Second Quarter 2032 [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	$ 10
Second Quarter 2032 [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price	$ 70

v3.24.1.1.u2

Schedule of Stock Outstanding Warrants Activity (Details)	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Warrants | shares	31,995
Weighted Average Price, Warrants	$ 56.49
Number of Shares, Issued | shares
Exercise Price, Issued
Weighted Average Price, Issued
Number of Shares, Expired and forfeited | shares
Exercise Price, Expired and forfeited
Weighted Average Price, Expired and forfeited
Number of Shares, Exercised | shares
Exercise Price, Exercised
Weighted Average Price, Exercised
Number of Shares, Warrants | shares	31,995
Weighted Average Price, Warrants	$ 56.49
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price, Warrants	10
Exercise Price, Warrants	10
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise Price, Warrants	70
Exercise Price, Warrants	$ 70

v3.24.1.1.u2

Income Taxes – Results of Operations (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax expense benefit	$ 0	$ 0
Statutory income tax rate	21.00%	21.00%

---